Document Type
Article
Department
Office of the Provost
Abstract
Health technology assessment (HTA) can be used to make healthcare systems more equitable and efficient. Advances in precision oncology are challenging conventional thinking about HTA. Precision oncology advances are rapid, involve small patient groups, and are frequently evaluated without a randomized comparison group. In light of these challenges, mechanisms to manage precision oncology uncertainties are critical. We propose a life-cycle HTA framework and outline supporting criteria to manage uncertainties based on real world data collected from learning healthcare systems. If appropriately designed, we argue that life-cycle HTA is the driver of real world evidence generation and furthers our understanding of comparative effectiveness and value. We conclude that life-cycle HTA deliberation processes must be embedded into healthcare systems for an agile response to the constantly changing landscape of precision oncology innovation. We encourage further research outlining the core requirements, infrastructure, and checklists needed to achieve the goal of learning healthcare supporting life-cycle HTA.
Publication (Name of Journal)
NPJ Precision Oncology
DOI
10.1038/s41698-022-00316-1
Recommended Citation
Regier, D. A.,
Pollard, S.,
McPhail, M.,
Bubela, T. M.,
Hanna, T. P.,
Ho, C.,
Lim, H. J.,
Chan, K.,
Peacock, S. J.,
Weymann, D.
(2022). A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada. NPJ Precision Oncology, 6(1), 76.
Available at:
https://ecommons.aku.edu/provost_office/719
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Comments
Pagination is not provided by the author/publisher. This work was published before Tania joined Aga Khan University.